Initially, mitoNEET was identified as a mitochondrial target of thiazolidinediones such as pioglitazone and rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, a class of medicines used to treat type-2 diabetes [28, 29]. Here, PPARG is linked to type 2 diabetes mellitus.